Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.
(1) Of the four anticholinesterases available in France for the treatment of mild to moderate Alzheimer's disease, donepezil is the reference agent. (2) Yet even donepezil is only moderately effective: only about 10% of patients show a short-lived clinical improvement. (3) Recent systematic reviews from Cochrane and NICE confirm the moderate efficacy of anticholinesterases in this setting.